利髓汤系列方治疗低危型骨髓增生异常综合征的临床研究

目的 观察利髓汤系列方治疗低危型骨髓增生异常综合征(myelodysplastic syndrome,MDS)的临床疗效.方法 将69例低危型MDS患者随机分为两组,治疗组35例以利髓汤系列方为主辨证治疗;对照组34例口服康力龙,RAS加服维生素B6治疗,观察临床疗效、外周血象、T-细胞亚群及骨髓象等的变化.结果 治疗组与对照组基本缓解率、总有效率分别为8.57%、2.94%及71.4%、38.2%,治疗后治疗组较对照组外周血常规、T-细胞亚群百分率、骨髓红系病态造血细胞及临床症状均有显著性差异.结论 利髓汤系列方治疗低危型MDS有良效.

Clinical Observation on the Treatment of Myelodysplastic Syndrome of Low Risk Type with

Objective To observe the effect of Lisui Decoction in treating low-risk type myelodysplastic syndrome (MDS).Methods 79 such cases were randomly divided into a group treatment group with 45 cases and a control group with 34 cases.The treatment group Was treated wim Lisui Decoction and the control group was treated with Stanozolol RAS and vitamin B6.Such indexes as clinical curative effects,peripheral blood,and changes of T cell phenotypic subpopulations and medulla picture were observed.Results There was between the treatment group and the control group.The CR rate was 8.57%and 2.94%.and the total effective rate was 71.1%and 38.2%in the treatment group and the control group respectively,showing significant difierence.The peripheral blood.T cell phenotypic subpopulations and the dysplastic hematopoiesis in erythroid also showed significant difiefences.Conclusion Lisui Decoction can improve hematopoiesis of bone marrow and it is effective in treating low-risk type myelodysplastic syndrome.